Securing and maintaining market authorization from the U.S. Food and Drug Administration (FDA) is the most critical hurdle for life science organizations. A single regulatory delay, Pre-Approval Inspection (PAI) deficiency, or Form 483 observation can stall commercial clinical trials, delay product launches, and result in millions of dollars in lost market value.
At OAAK Biosolutions, we offer specialized FDA compliance consulting services designed to safeguard your regulatory filings and operational status. From structuring compliant IND, NDA, and BLA submissions to managing enforcement actions (Form 483s and Warning Letters), our seasoned regulatory experts ensure your organization aligns with current FDA expectations and 21 CFR regulatory frameworks.
Our FDA compliance advisory focuses on regulatory governance, enforcement defense, and agency interactions.
The FDA conducts Pre-Approval Inspections to verify that manufacturing facilities and analytical testing match clinical submission data.
PAI Mock Inspections: Conducting simulated FDA audits using real-world agency questioning techniques and documentation requests.
Data Integrity Audits: Verifying complete traceability between laboratory raw data, batch production records, and regulatory dossiers.
Subject Matter Expert (SME) Coaching: Training facility personnel and management on how to interact professionally with FDA investigators.
Receiving an official FDA enforcement observation requires immediate, structured, and scientifically sound intervention.
15-Day Response Strategy: Drafting objective, comprehensive, and legally compliant 15-day response letters to Form 483 observations.
Root Cause & CAPA Execution: Establishing systemic Corrective and Preventive Action (CAPA) plans to address underlying agency concerns.
FDA Meeting Representation: Supporting executive leadership during Regulatory Action Meetings (RAM) and agency debriefs.
Modern biopharma operations rely heavily on computerized systems, requiring strict electronic record and signature compliance.
Computer System Validation (CSV): Validating LIMS, eQMS, ERP, and automated manufacturing equipment under 21 CFR Part 11 rules.
Audit Trail Reviews: Establishing routine data governance and audit trail verification procedures to prevent data falsification or loss.
Proactive alignment with FDA officials ensures smooth clinical transition and expedited product reviews.
Meeting Preparation (Type A, B, C): Assembling comprehensive briefing packages for Pre-IND, End-of-Phase 2, and Pre-BLA/NDA agency meetings.
Special Designation Submissions: Strategic drafting for Fast Track, Breakthrough Therapy, Orphan Drug, and RMAT applications.
Regulatory Gap Assessment: Full review of current regulatory commitments, filing histories, and data integrity vulnerabilities.
Remediation Plan Development: Priority-ranked action plan specifying resource allocation, CAPA milestones, and target timelines.
Execution & Submission Support: On-site execution of CSV validation, policy rewriting, and agency response drafting.
Post-Audit Verification: Final mock walkthroughs and monitoring to confirm sustained compliance ahead of re-inspection.
Strategic remediation support to handle FDA Form 483 observations, Warning Letters, and enforcement actions with robust 15-day responses and root-cause CAPA plans.
End-to-end Computer System Validation (CSV), eQMS alignment, and digital audit trail reviews to ensure full compliance with FDA electronic record and signature regulations.
Comprehensive mock FDA inspections, Subject Matter Expert (SME) coaching, and complete raw-data-to-dossier traceability verification to guarantee PAI audit readiness.
End-to-end guidance for IND, NDA, and BLA filings, meeting preparation (Type A, B, C) with FDA officials, and strategic submissions for expedited regulatory designations.
A company has exactly 15 business days from the issuance of an FDA Form 483 to submit a formal written response. A complete, scientific, and acceptable response within this window is critical to avoiding a formal Warning Letter.
21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures. It ensures that digital records are trustworthy, reliable, and equivalent to paper records through strict audit trails, system security, and validation protocols.
We conduct mock interview sessions, teach Subject Matter Experts (SMEs) how to answer investigator questions directly without over-explaining, and establish cleanroom “front room / back room” audit management protocols.
Avoid regulatory enforcement actions and secure smooth FDA product approvals. Partner with OAAK Biosolutions for world-class FDA compliance consulting.